Drugs / DKF-5122
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05749380 | Sep 2020 → Jan 2022 | fungal infectious disease, neutropenia | Dongkook Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DKF-5122 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05749380 ↗ |
| Known as | Amphosom | “PURPOSE: This study evaluated the bioequivalence of a newly developed liposomal amphotericin B (LAmB) formulation (DKF-5122, Amphosom™) relative to AmBisomeⓇ and...” PMID 41513548 ↗ Jan 2026 |
| Route | Intravenous | “Both cohorts received 3 mg/kg intravenously” PMID 41513548 ↗ Jan 2026 |